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| INTRODUC TI ON
Pancreatic cancer is an extremely malignant cancer, with a 5-year survival rate of <5%. Although surgical resection is the only possible curative treatment, this cancer is often advanced and metastasized when diagnosed. 1 Standard chemotherapies for pancreatic cancer provide only slightly increased survival periods owing to high resistance and aggressiveness that has been associated with the tumor microenvironment such as collagen deposition, high number of activated CAF and increased inflammatory cell infiltration. [2] [3] [4] [5] We have isolated VASH1 as an endothelium-derived angiogenesis inhibitor, 6 and VASH2 as its homolog. 7 Although VASH1 and VASH2 have no classical signal sequence for their secretion, they are efficiently secreted through binding with another newly discovered protein, SVBP (small vasohibin binding protein). 8 The VASH gene is highly conserved between species. Lower organisms possess a single ancestral VASH gene, which has evolved into VASH1 and VASH2 genes in vertebrates. Whereas VASH1 is expressed in endothelial cells, VASH2, which is more similar to the ancestral VASH,
is not expressed in normal tissues except in the testis after birth. 9 However, VASH2 is overexpressed in various cancer cells, and promotes tumor angiogenesis, accumulation of CAF and EMT of cancer cells. [10] [11] [12] [13] [14] VASH2 knockdown or blockade in cancer cells including human ovarian cancer and hepatocellular carcinoma showed significant anticancer effects, 10, 11, 15, 16 and VASH2 has consequently been identified as a potential molecular target for anticancer therapy.
Microtubules (MT) are a major component of cytoskeletons, and show important functions ranging from intracellular transport to cell motility and cell division. MT are composed of repeating α-and β-tubulin heterodimers, and they are subjected to a number of post-translational modifications including the tyrosination-detyrosination cycle. Tubulin tyrosination is mediated by tubulin tyrosine ligase whereas its detyrosination is mediated by TCP. One such modification, namely tubulin detyrosination, is reported to be accumulated in cancer cells during tumor development and is correlated with histological grade in breast cancer. 17, 18 VASH have recently been identified to have TCP activity, which catalyzes the C-terminus tyrosine residue of α-tubulin. 19, 20 Thus, VASH2 may influence cancer cell behavior by augmenting tubulin detyrosination.
We recently showed VASH2 expression in KPC cell lines and that its expression correlates with poor prognosis in PDAC patients. 21 Furthermore, VASH2 amplification occurs frequently in primary PDAC (10%). 22 
| Cell culture
Murine pancreatic cancer cells (KPC cells) were isolated from the tumors of KPC mice as described previously. 25 
| Adenoviral infection
For VASH2 overexpression in SUIT-2, we used adenovirus vectors encoding human VASH2 (AdVASH2). 24 SUIT-2 cells were plated in 
| Cell proliferation assay
Cells were plated in 96 wells at 3 × 10 3 cells/well and cultured overnight at 37°C in DMEM containing 10% FBS. Subsequently, at different time points (0, 24, 48, 72 hours), 10 μL cell proliferation reagent WST-1 (Sigma-Aldrich) was added and cells were further incubated for 1 hour at 37°C. Absorbance was then determined at 450 nm.
| Cell migration and invasion assays
Cell migration was determined using a 24-well Transwell with 
| Western blot analysis
Cells were harvested from the culture dish with a scraper in RIPA buffer containing 0.1% SDS (Nakalai Tesque, Kyoto, Japan). Equal amounts of proteins were separated by SDS-PAGE, blotted onto PVDF membranes (Bio-Rad, Hercules, CA, USA 
| Quantitative real-time reverse transcriptasepolymerase chain reaction
For preparation of total RNA from cultured cells and mouse tissue, total RNA was isolated using an RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
Complementary DNA was prepared from total RNA using ReverTra Ace (ToYoBo, Osaka, Japan). qRT-PCR was carried out using a CFX96
real-time PCR detection system (Bio-Rad) according to the manufacturer's instructions. Each mRNA level was measured and normalized to β-actin. Sequences of the primers are shown in Table S1 .
| Microarray analysis
KPC/shControl cells and KPC/shVash2 cells were harvested and total RNA was extracted as described above. RNA integrity was confirmed by Agilent 2100 bioanalyzer (Agilent Technologies, Santa, Clara, CA, USA). Briefly, total RNA was converted to cDNA, followed by in vitro transcription and labeling of Cy3-CTP into nascent cRNA. After labeling, cRNA was subjected to Agilent SurePrint G3 Mouse GE 8 × 60K
Microarrays (Agilent Technologies). Fluorescence signals were scanned as described in the manufacturer's protocol. Signal intensities were calculated by Feature Extraction Software (Agilent Technologies). 
| Transfection and luciferase assays
| Immunohistochemical analysis
Tumor tissues were fixed with 4% formalin, dehydrated in etha- 
| Statistical analysis
Data are expressed as mean and standard deviation (SD) or standard error of means (SEM). For determining differences between two groups, data were analyzed using the Student's t test. For a comparison of more than two groups, Holm-Bonferroni test was used. For
Kaplan-Meier plots, log-rank test was applied for statistical analyses.
P-value <.05 was considered statistically significant.
| RE SULTS
| Vasohibin-2 is expressed in PDAC cells and promotes their migration
To examine the role of Vash2 in pancreatic cancer, we used KPC mice in which oncogenic Kras G12D and TP53 R172H were conditionally expressed under the control of the pancreas-specific Pdx-1 promoter. 23 We first analyzed Vash2 expression in samples from KPC mice at each stage, and found that Vash2 was significantly upregulated in pancreatic tissue during PDAC progression ( Figure 1A) . We then used a pancreatic cancer cell line derived from PDAC of a KPC mouse (KPC cells), 25 and established two sta- S1 ). The human pancreatic cancer cell line PANC-1 also showed decreased cell migration when VASH2 was stably knocked down ( Figure 1E ). Conversely, VASH2 overexpression significantly increased migration of human pancreatic cancer cell line SUIT-2 in which endogenous VASH2 was almost absent ( Figure 1F ).
These data indicate that VASH2 expression is increased during PDAC progression, and promotes PDAC cell migration.
| Vasohibin-2 is required for PDAC progression
To determine whether Vash2 is involved in the metastasis of PDAC, we injected KPC cells into the tail vein of nude mice. Lung metastasis was significantly decreased in the mice injected with These results indicate that Vash2 plays an essential role in PDAC metastasis.
| Vasohibin-2 increases α-tubulin detyrosination for cancer cell migration
Our previous study showed that VASH2 modulates the metastatic potential of tumor cells through EMT by regulation of transforming growth factor beta (TGF-β) signaling in ovarian cancer cells. 13 We confirmed EMT markers in KPC cell lines and PDAC in KPC mice.
Vash2-knockdown did not affect E-cadherin and vimentin protein levels nor TGF-β and TGF-βRI mRNA levels in the KPC cell line ( Figure S3A,B) . Furthermore, IHC analyses showed that no significant changes were observed in E-cadherin level in KPC/Vash2
LacZ/LacZ mice ( Figure S3C ). These results indicate that EMT may not be the major cause of VASH2-induced metastatic potential.
Vasohibins have recently been identified to have TCP activity, which deletes a tyrosine residue from the carboxy-terminus of α-tubulin. 19, 20 We confirmed that detyrosinated tubulin was decreased in Vash2-knockdown KPC cells and tissue of orthotopic tumors ( Figure 4A-C) . Conversely, VASH2 overexpression strongly increased detyrosinated tubulin and cell migration of SUIT-2 ( Figure 4D ). We then asked if this TCP activity was related to cell migration. When VASH2-overexpressed SUIT-2 cells were treated with a TCP inhibitor parthenolide, 26 the increased cell migration was almost completely inhibited ( Figure 4E) . Thus, the TCP activity of VASH2 is required for cancer cell migration and metastasis.
| Role of VASH2 in tumor angiogenesis
As we previously noted that VASH2 accelerated tumor angiogenesis, 10, 12 we examined the vasculature in the orthotopic tumors. Vascular area was significantly reduced in tumors formed 
| Role of VASH2 in the tumor immune microenvironment
To further clarify VASH2 function, the downstream targets of VASH2 in KPC cells were analyzed using microarray to compare gene expression between control and Vash2-knockdown KPC cells. Microarray showed that 911 genes were upregulated and 1695 genes were downregulated by Vash2 knockdown in KPC cells (<0.5 fold). Gene enrichment analysis by KEGG pathway showed that downregulated genes were related to inflammation, including cytokine-cytokine receptor interaction, chemokine signaling and tumor necrosis factor (TNF) signaling ( Figure 6A ). NF-κB signaling is a classical proinflammatory signaling pathway, and we therefore assessed NF-κB activity using a pNF-κB-MetLuc2 reporter vector which contained multiple copies of the NF-κB response element. Knockdown of Vash2 decreased NF-κB promoter activity ( Figure 6B ). We further examined gene expression included in these pathways using RT-qPCR, and downregulation of secreted proteins such as chemokines (Cxcl2, Cxcl5, Ccl2, Ccl5) and cytokines (Csf1, Csf2, Il-1A) were observed ( Figure 6C ). CXCL2 and CXCL5 are ligands for CXCR2, which is expressed in G-MDSC and neutrophils. 27 These ligands recruit G-MDSC, which enable evasion of tumor immunity in PDAC. 4 Csf2 encodes the cytokine GM-CSF, and tumor-derived GM-CSF drives differentiation of G-MDSC. 28 We confirmed downregulation of CXCR2 ligands and GM-CSF mRNA expression ( Figure 6D ), and also CXCL1 protein levels ( Figure S4 ). 
| Vasohibin-2 is involved in the evasion of tumor immunity
Accumulation of G-MDSC prevents cytotoxic T-cell infiltration into the tumor, and this supports tumor progression in PDAC. 4 We speculated that VASH2 modulates G-MDSC accumulation through the upregulation of CXCR2 ligands and GM-CSF. We therefore examined the presence of CD11b + Ly6G + G-MDSC by immunohistochemical double staining. Quantification of G-MDSC in tumor showed that G-
MDSC accumulation was decreased in PDAC of KPC/Vash2
LacZ/LacZ mice ( Figure 7A ). We next investigated T-cell infiltration in the tumor. Macrophages are broadly divided into proinflammatory M1-TAM and anti-inflammatory M2-TAM. 30 We showed that deletion of the 
| D ISCUSS I ON
Pancreatic ductal adenocarcinoma is a highly metastatic cancer.
Herein, we examined the significance of VASH2 in PDAC, and showed that VASH2 plays an essential role in the progression of PDAC by acting on both cancer cells and the tumor microenvironment.
VASH2 knockdown significantly reduced pancreatic cancer cell migration, whereas its overexpression increased their migration.
Accordingly, the VASH2-induced cell migration was due to its direct effect on PDAC cells. Although we and others have previously shown to have TCP activity. 19, 20 In accordance with this evidence, the present study showed that VASH2 stimulated metastatic activity of PDAC cells, at least in part, through its TCP activity within the cell. Accumulation of detyrosinated tubulin is documented in breast cancers and neuroblastomas with poor prognosis. 18, 31 In addition, detyrosinated tubulin is involved in the metastasis of breast cancer cells though the formation of cellular protrusions, so-called microtentacles. 26 We suggest that VASH2 may play a considerable role in the accumulation of detyrosinated tubulin in such circumstances.
When bound to SVBP, VASH2 is efficiently secreted, 8, 32 and this may be responsible for the paracrine effect of VASH2 in the tumor microenvironment. We have previously reported that when VASH2
was knocked down in cancer cells, it prevented tumor angiogenesis in ovarian cancer cells and hepatocellular carcinoma. 10, 11 In addition, neutralizing anti-VASH2 monoclonal antibody can inhibit VASH2-induced tumor angiogenesis. 16 Thus, VASH2 secreted by cancer cells stimulates tumor angiogenesis, and our present study supports this theory. We evaluated and determined that cell proliferation in vitro was not affected by VASH2 expression levels, whereas tumor weights were decreased in vivo by VASH2 knockdown. 
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